Product
efatutazone
2 clinical trials
3 indications
Indication
LiposarcomaIndication
Anaplastic Thyroid CancerIndication
Recurrent Thyroid CancerClinical trial
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid LiposarcomaStatus: Completed, Estimated PCD: 2018-10-04
Clinical trial
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid CancerStatus: Completed, Estimated PCD: 2019-02-27